Invesco increase holdings in Motif Bio Plc to over 25%

TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES

1. Identity of the issuer or the underlying issuer
of existing shares to which voting rights are
attached:

Motif Bio Plc

2 Reason for the notification (please tick the appropriate box or boxes):

An acquisition or disposal of voting rights

Yes

An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached

No

An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments

No

An event changing the breakdown of voting rights

No

Other (please specify):

No

3. Full name of person(s) subject to the
notification obligation:

Invesco Limited

4. Full name of shareholder(s)
 (if different from 3.):

5. Date of the transaction and date on
which the threshold is crossed or
reached:

19 February 2016

6. Date on which issuer notified:

22 February 2016

7. Threshold(s) that is/are crossed or
reached:

24%, 25%

 

8. Notified details:

A: Voting rights attached to shares

Class/type of
shares

if possible using
the ISIN CODE

Situation previous
to the triggering
transaction

Resulting situation after the triggering transaction

Number
of
Shares

Number
of
Voting
Rights

Number
of shares

Number of voting
rights

% of  voting rights

Direct

Direct

Indirect

Direct

Indirect

Ordinary 0.1p Shares

 

25,000,000

25,000,000

27,600,000

25.41%

Click to view all articles for the EPIC:
Or click to view the full company profile:
    Facebook
    X
    LinkedIn
    Motif Bio Plc

    More articles like this

    Motif Bio Plc

    Motif Bio plc Proposed Placing to raise approximately £19.4m

    Motif Bio plc (LON:MTFB), the clinical stage biopharmaceutical company specialising in developing novel antibiotics, announced today its intention to raise approximately £19.4 million (US$25 million), before expenses, by way of a conditional placing with new and

    Motif Bio Plc

    Motif Bio PLC Reports Year-End 2016 Financial Results

    Motif Bio PLC (LON:MTFB), a clinical stage biopharmaceutical company specializing in developing novel antibiotics, today announced financial results for the year ended December 31, 2016. Motif Bio made significant progress in 2016 towards our goal of

    Motif Bio Plc

    Motif Bio plc Update post NASDAQ IPO

    Motif Bio plc (LON:MTFB, NASDAQ:MTFB), is a late clinical stage antibiotic development company. The company completed its IPO on NASDAQ in November last year raising $25m before expenses. With the funds from the IPO the company

    Motif Bio Plc

    Motif Bio plc appoint ex NASDAQ listed Tyme Technologies CFO

    Motif Bio plc (AIM: MTFB), the clinical stage biopharmaceutical company specialising in developing novel antibiotics, has told DirectorsTalk that Robert Dickey IV has been appointed as Chief Financial Officer. Mr. Dickey is an accomplished financial professional

    Motif Bio Plc

    Motif Bio PLC Update on US Public Offering

    Motif Bio plc (LON:MTFB), the clinical stage biopharmaceutical company specialising in developing novel antibiotics, further to its announcement of 9 August 2016, said today that it is continuing to work towards pricing of its proposed public

    Motif Bio Plc

    Motif Bio plc 2 posters at ID Week in New Orleans

    Motif Bio plc (AIM: MTFB), the clinical stage biopharmaceutical company specialising in developing novel antibiotics, has told DirectorsTalk that it will be presenting two poster studies at IDWeek, October 26 to 30 in New Orleans, USA.

    Motif Bio Plc

    Motif Bio plc progressing trials efficiently with latest update

    Motif Bio plc (AIM: MTFB), the clinical stage biopharmaceutical company specialising in developing novel antibiotics, has given DirectorsTalk an update to REVIVE-1, one of Motif Bio’s two Phase 3 clinical trials currently enrolling patients with Acute